Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines
- PMID: 18813952
- DOI: 10.1007/s00432-008-0475-2
Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines
Abstract
Objective: The aim of this study was to investigate the effect of epidermal growth factor receptor (EGFR) blockade on cell survival and on downstream signalling pathways using the monoclonal antibody cetuximab.
Methods: We used three colon cancer cell lines, of which one was EGFR-negative, and two head and neck squamous cell carcinoma (HNSCC) lines. EGFR expression and gene copy number were measured by immunohistochemistry and FISH analysis, respectively. The effect of cetuximab, irradiation or the combination of both on cell growth was estimated by SRB assay. Western blotting was used to determine the phosphorylation of intracellular signalling proteins and cell cycle phase distribution was measured by flow cytometry.
Results: The addition of cetuximab had only limited effects on cell growth, with a maximum inhibition of approximately 30%, but was correlated with the amount of protein expression and gene copy number of EGFR. When combined with irradiation, the effect of cetuximab was only additive and not dependent on the inherent radio-sensitivity of the cell lines. Persistent phosphorylation of Akt and/or p44/42 MAPK was detected by western blot in all of the cell lines, whereas there was no phosphorylation of Jak2 or STAT3.
Conclusions: None of these factors alone could predict the sensitivity to cetuximab. Rather, the results suggest that it might be necessary to determine the activation status of several intracellular signalling proteins to better predict the sensitivity to cetuximab treatment.
Similar articles
-
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.Clin Cancer Res. 2006 Jul 1;12(13):4103-11. doi: 10.1158/1078-0432.CCR-05-2404. Clin Cancer Res. 2006. PMID: 16818711
-
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.PLoS One. 2013;8(2):e56112. doi: 10.1371/journal.pone.0056112. Epub 2013 Feb 6. PLoS One. 2013. PMID: 23405260 Free PMC article.
-
Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling.Cancer Invest. 2010 Oct;28(8):775-87. doi: 10.3109/07357907.2010.483506. Cancer Invest. 2010. PMID: 20504227
-
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30. doi: 10.1053/sonc.2002.35644. Semin Oncol. 2002. PMID: 12422310 Review.
-
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.Drugs Today (Barc). 2005 Feb;41(2):107-27. doi: 10.1358/dot.2005.41.2.882662. Drugs Today (Barc). 2005. PMID: 15821783 Review.
Cited by
-
Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.Oncologist. 2013;18(7):850-64. doi: 10.1634/theoncologist.2013-0013. Epub 2013 Jul 2. Oncologist. 2013. PMID: 23821327 Free PMC article. Review.
-
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Head Neck. 2014 Nov;36(11):1547-54. doi: 10.1002/hed.23499. Epub 2014 Mar 20. Head Neck. 2014. PMID: 24123531 Free PMC article.
-
Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.Am J Cancer Res. 2015 Jan 15;5(2):560-74. eCollection 2015. Am J Cancer Res. 2015. PMID: 25973297 Free PMC article.
-
Increased toxicity of a trinuclear Pt-compound in a human squamous carcinoma cell line by polyamine depletion.Cancer Cell Int. 2012 May 28;12(1):20. doi: 10.1186/1475-2867-12-20. Cancer Cell Int. 2012. PMID: 22640800 Free PMC article.
-
The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy.Front Oncol. 2021 Sep 10;11:697967. doi: 10.3389/fonc.2021.697967. eCollection 2021. Front Oncol. 2021. PMID: 34568028 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous